HIGH

Cipla Recalls Cinacalcet Hydrochloride Tablets Over Impurity Risk

Cipla USA, Inc. recalled 63,504 bottles of Cinacalcet Hydrochloride Tablets on November 14, 2025. The recall results from a nitrosamine impurity, N-nitroso-cinacalcet, exceeding acceptable daily intake limits. Consumers should stop using the tablets immediately and contact healthcare providers for guidance.

Quick Facts at a Glance

Recall Date
November 14, 2025
Hazard Level
HIGH
Brands
CINACALCET, Cipla USA Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Cinacalcet Hydrochloride Tablets are used to treat conditions related to elevated parathyroid hormone levels, often prescribed for patients with chronic kidney disease or hyperparathyroidism. Patients buy these tablets for their potential to manage calcium and phosphorus levels in the body effectively.

Why This Is Dangerous

The recall is due to the presence of N-nitroso-cinacalcet, a nitrosamine impurity, which exceeds acceptable levels. Nitrosamines can form during the manufacturing process and have been linked to cancer risk.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers must stop using the product immediately due to the potential health risks associated with nitrosamine exposure. This may lead to inconvenience as patients seek alternatives or consult their healthcare providers.

Practical Guidance

How to identify if yours is affected

  1. Check the bottle for the lot numbers: 4PB0109 or 5PB0172.
  2. Verify the expiry dates: 1/31/2026 or 1/31/2027.
  3. If you have purchased Cinacalcet Hydrochloride Tablets, confirm your product matches the recalled lots.

Where to find product info

Lot numbers and expiration dates are typically printed on the label or the bottom of the bottle.

What timeline to expect

Expect a refund or replacement to be processed within 4-6 weeks after returning the product.

If the manufacturer is unresponsive

  • Keep records of your communication with the company.
  • Reach out again, or escalate your inquiry to a consumer protection agency.

How to prevent similar issues

  • Always check for recalls before using prescription medications.
  • Consult your physician about potential alternatives if a recall occurs.

Documentation advice

Document your purchase by keeping receipts and any correspondence with the manufacturer regarding the recall.

Product Details

The recall involves Cinacalcet Hydrochloride Tablets, 30 mg, sold in bottles of 30 tablets. The affected lot numbers are 4PB0109 (expiry 1/31/2026) and 5PB0172 (expiry 1/31/2027). These tablets were distributed nationwide in the U.S.

Key Facts

  • Recall date: November 14, 2025
  • Quantity recalled: 63,504 bottles
  • Affected lot numbers: 4PB0109, 5PB0172
  • Health risk: Nitrosamine impurity
  • Immediate action required

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeCinacalcet Hydrochloride Tablets
Sold At
Multiple Retailers

Product Details

Model Numbers
Lot
expiry: Lot 4PB0109
exp 1/31/2026
Lot 5PB0172
exp 1/31/2027
UPC Codes
69097-410
69097-411
69097-412
+3 more
Affected States
ALL
Report Date
December 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more